Evidence map›Paper›PMID 27059089›Full record

ReviewMolecular nutrition & food research2016

Dietary flavonoid fisetin for cancer prevention and treatment.

Rahul K Lall, Vaqar Mustafa Adhami, Hasan Mukhtar

Open access · greenAbstract readReview
In one paragraph

Review in Molecular nutrition & food research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 2 pooled it
12.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 2 syntheses or guidelines pooled it, 142 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Flavonoids as colchicine binding site inhibitors: emerging scaffolds in anticancer drug design.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026
    Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Modulation ofPeerJ · 2025
    Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Himalayan flora: targeting various molecular pathways in lung cancer.Medical oncology (Northwood, London, England) · 2023
    Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Rahul K LallDepartment of Food Science, University of Wisconsin-Madison, Madison, WI, USA.
Vaqar Mustafa AdhamiDepartment of Dermatology, University of Wisconsin-Madison, Madison, WI, USA.
Hasan MukhtarDepartment of Dermatology, University of Wisconsin-Madison, Madison, WI, USA.
University of Wisconsin–Madison · US

Funding

Developing Fisetin for the Managment of Prostate CancerR01CA160867 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI MUKHTAR, HASAN · 2011 to 2015
$1.6M
NCI NIH HHS R01 CA160867
6 · The paper itself

Abstract

Cancer remains a major public health concern and a significant cause of death worldwide. Identification of bioactive molecules that have the potential to inhibit carcinogenesis continues to garner interest among the scientific community. In particular, flavonoids from dietary sources are the most sought after because of their safety, cost-effectiveness, and feasibility of oral administration. Emerging data have provided newer insights into understanding the molecular mechanisms that are essential to identify novel mechanism-based strategies for cancer prevention and treatment. Dietary flavonoid fisetin (3,3',4',7-tetrahydroxyflavone) found in many fruits and vegetables has been shown in preclinical studies to inhibit cancer growth through alteration of cell cycle, inducing apoptosis, angiogenesis, invasion, and metastasis without causing any toxicity to normal cells. Although data from in-vitro and in-vivo studies look convincing, well-designed clinical trials in humans are needed to conclusively determine the efficacy across various cancers. This review highlights the chemopreventive and therapeutic effects, molecular targets, and mechanisms that contribute to the observed anticancer activity of fisetin against various cancers.

Indexed as

AnimalsAnticarcinogenic AgentsCarcinogenesisCell Line, TumorChemopreventionFemaleFlavonoidsFlavonolsFruitHumansMaleNeoplasmsPolyphenolsVegetablesAnticarcinogenic AgentsfisetinFlavonoidsFlavonolsPolyphenolsCancerChemopreventionDietFisetinFlavonoid

Identifiers

PMID27059089
PMCPMC6261287
OpenAlexW2312957701

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.